During his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology. Read more
During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies. Read more
Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case. Read more
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies. Read more
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care. Read more
Dr. Lucia Viola says that access to genomic profiling is crucial for gathering information about patients who do not smoke. Read more
Dr. Stella Martinez recently shared the latest data and explored the challenges and opportunities in lung cancer surgery in Latin America. Read more
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment. Read more
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives. Read more
Prof. Glenwood Goss said adjuvant durvalumab did not improve disease-free survival outcomes following complete resection and optional chemotherapy. Read more